- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05217810
Een 24 weken durend prospectief, open-label, multicenter, eenarmig rPMS-onderzoek in real-world setting voor Atectura®
Een 24 weken durende prospectieve, open-label, multicenter, single-arm Regulatory Post-Marketing Surveillance (rPMS)-studie in real-world setting (verplicht door lokale HA-regelgeving) voor Atectura® (QMF149 150/80 μg o.d., QMF149 150/ 160 μg eenmaal daags en QMF149 150/320 μg eenmaal daags via Breezhaler)
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Busan, Zuid -Korea, 48108
- Novartis Investigative Site
-
Gyeongsangnam Do, Zuid -Korea, 51353
- Novartis Investigative Site
-
Jeju City, Zuid -Korea, 63241
- Novartis Investigative Site
-
Seoul, Zuid -Korea, 05505
- Novartis Investigative Site
-
Seoul, Zuid -Korea, 04763
- Novartis Investigative Site
-
Seoul, Zuid -Korea, 06273
- Novartis Investigative Site
-
Seoul, Zuid -Korea, 137 707
- Novartis Investigative Site
-
Taegu, Zuid -Korea, 41944
- Novartis Investigative Site
-
Ulsan, Zuid -Korea, 44033
- Novartis Investigative Site
-
-
Dalseo gu
-
Daegu, Dalseo gu, Zuid -Korea, 42602
- Novartis Investigative Site
-
-
Gangneung si
-
Kangwon Do, Gangneung si, Zuid -Korea, 210 711
- Novartis Investigative Site
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Zuid -Korea, 26426
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Zuid -Korea, 10380
- Novartis Investigative Site
-
Guri-si, Gyeonggi-do, Zuid -Korea, 11923
- Novartis Investigative Site
-
-
Gyeongsangnam-do
-
Jinju, Gyeongsangnam-do, Zuid -Korea, 52727
- Novartis Investigative Site
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Zuid -Korea, 54907
- Novartis Investigative Site
-
-
Jeonlabuk Do
-
Iksan Si, Jeonlabuk Do, Zuid -Korea, 54538
- Novartis Investigative Site
-
-
Korea
-
Daejeon, Korea, Zuid -Korea, 35015
- Novartis Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.
Beschrijving
Inclusion Criteria:
- Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
- Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)
Exclusion Criteria:
- Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
- Patients participating in other interventional clinical trials
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Atectura inhalation capsule (150/80ug)
Indacaterol acetate/Mometasone furoate; 150/80ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/160ug)
Indacaterol acetate/Mometasone furoate; 150/160ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/320ug)
Indacaterol acetate/Mometasone furoate; 150/320ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of adverse events and serious adverse events
Tijdsspanne: 24 weeks
|
Incidence of AE and SAE will be collected |
24 weeks
|
|
Incidence of unexpected adverse events and unexpected serious adverse events
Tijdsspanne: 24 weeks
|
Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label |
24 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
change from baseline in trough FEV1
Tijdsspanne: Baseline, week 12
|
Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. |
Baseline, week 12
|
|
change from baseline in ACT score
Tijdsspanne: Baseline, week 12
|
The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement. |
Baseline, week 12
|
|
Effective rate and ineffective rate by investigator assessment
Tijdsspanne: week 12
|
Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment |
week 12
|
|
Baseline characteristics of patients showing adverse events/adverse drug reactions
Tijdsspanne: 24 weeks
|
The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
24 weeks
|
|
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Tijdsspanne: 12 weeks
|
Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations |
12 weeks
|
|
Baseline characteristics of patients in relation to the investigator assessment
Tijdsspanne: 12 weeks
|
Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
12 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CQMF149EKR01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .